Clinical trials: Streptococcus Pneumoniae
Nasopharyngeal Carriage, Children, Only
Nasopharyngeal Carriage of S. Pneumoniae
This nasopharyngeal (NP) carriage surveillance study was requested by the European Agency for the Evaluation of Medicinal Products as a post-licensing commitment to determine whether the use of the pneumococcal conjugate vaccines…
- Conditions
- Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain
- Trial name
- NCT04460313
- Testing
- nasopharyngeal sample (mandatory), Stools collection or anorectal swab samples (optional), nasopharyngeal sample (optional)
- Where
- France
- Volunteers
- 29,360 people, healthy volunteers welcome
- Sponsor
- Association Clinique Thérapeutique Infantile du val de Marne
Pneumococcal Infections
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
A vaccine called Prevenar is already approved for use in China for vaccination of children younger than 6 years old against infections caused by Streptococcus pneumoniae.
- Trial name
- 6114A1-4000-CN (NCT01193582)
- Testing
- Prevenar
- Where
- 5 sites in China
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Safety and Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in 2 to 70 Years Old Healthy People in China
Pneumococcal infection is a leading cause of death throughout the world and a major cause of pneumonia, bacteremia, meningitis, and otitis media.
- Trial name
- NCT01451086
- Testing
- vaccine made by Beijing Minhai Biotechnology Co., Ltd, vaccine made by Chengdu Institute of Biological Products
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years…
- Trial name
- NCT00521586
- Testing
- 13 valent pneumococcal conjugate vaccine
- Where
- 41 sites in United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccine, Streptococcus Pneumoniae
Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma
The French Public Health Council recommended pneumococcal vaccination combined strategy for all immunocompromised patients in 2012.
- Conditions
- Vaccine, Streptococcus Pneumoniae, Lymphoma, Non-Hodgkin
- Trial name
- HEMATOVAC (NCT04460235)
- Testing
- Prevenar 13 + Pneumovax 23, PREVENAR20
- Where
- 7 sites in France
- Volunteers
- 160 people
- Sponsor
- Poitiers University Hospital
Vaccines, Pneumococcal
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to 7-valent pneumococcal conjugate (Prevenar/Prevenar®, 7vPnC), when given…
- Trial name
- NCT00366340
- Testing
- 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine
- Where
- 51 sites in Germany
- Volunteers
- 604 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vaccine-Preventable Diseases
Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity
Rationale Causing a wide range of infectious diseases, including pneumonia, otitis media and meningitis, S. pneumoniae represents an important global health problem.
- Trial name
- SEA (NCT06202703)
- Testing
- Pneumococcal Vaccine
- Where
- Netherlands
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Immune Tolerance
Pneumococcal Conjugate Vaccine Followup
Recently, controversy has emerged regarding the role of the 23vPPV in infants due to potential immunological hypo-responsiveness (i.e. a poorer immune response to repeat vaccination).
- Trial name
- PCVFU (NCT01414504)
- Testing
- Prevenar + PPV, Infant PCV (Prevenar) + PPV at 9 months, No Prevenar + PPV at 9 months
- Where
- Papua New Guinea
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- William Pomat